TW211568B - - Google Patents

Download PDF

Info

Publication number
TW211568B
TW211568B TW081110173A TW81110173A TW211568B TW 211568 B TW211568 B TW 211568B TW 081110173 A TW081110173 A TW 081110173A TW 81110173 A TW81110173 A TW 81110173A TW 211568 B TW211568 B TW 211568B
Authority
TW
Taiwan
Prior art keywords
compound
cyclopropyl
group
quinazoline
gas
Prior art date
Application number
TW081110173A
Other languages
English (en)
Chinese (zh)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of TW211568B publication Critical patent/TW211568B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW081110173A 1991-12-20 1992-12-18 TW211568B (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK912042A DK204291D0 (da) 1991-12-20 1991-12-20 Heterocykliske forbindelser deres fremstilling og anvendelse

Publications (1)

Publication Number Publication Date
TW211568B true TW211568B (cs) 1993-08-21

Family

ID=8109668

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081110173A TW211568B (cs) 1991-12-20 1992-12-18

Country Status (12)

Country Link
EP (1) EP0619820A1 (cs)
JP (1) JPH07502278A (cs)
AU (1) AU673814B2 (cs)
CA (1) CA2125854A1 (cs)
DK (1) DK204291D0 (cs)
FI (1) FI942963A7 (cs)
IL (1) IL104099A (cs)
NO (1) NO942301L (cs)
NZ (1) NZ246558A (cs)
TW (1) TW211568B (cs)
WO (1) WO1993013103A1 (cs)
ZA (1) ZA929770B (cs)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK151890D0 (da) * 1990-06-22 1990-06-22 Ferrosan As Heterocykliske forbindelser deres fremstilling og brug
CN1052724C (zh) * 1996-07-01 2000-05-24 瑞安大药厂股份有限公司 新的光学活性的2,3－二氢咪唑并[1,2－c]喹唑啉衍生物及其制备方法和用途
KR100864364B1 (ko) 2005-12-13 2008-10-17 주식회사 엘지화학 신규한 이미다조퀴나졸린 유도체, 이의 제조방법 및 이를이용한 유기전기소자
CA2678577A1 (en) 2007-02-26 2008-09-04 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
AR069207A1 (es) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
WO2009075835A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceutical, Inc CYCLIC UREA INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE 1
RU2539979C2 (ru) 2008-07-25 2015-01-27 Вайтаи Фармасьютиклз, Инк. Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1
JP5777030B2 (ja) 2008-07-25 2015-09-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １１β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤
CA2744946A1 (en) 2009-02-04 2010-08-12 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
UA109255C2 (ru) 2009-04-30 2015-08-10 Берінгер Інгельхайм Інтернешнл Гмбх Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1
EP2440537A1 (en) 2009-06-11 2012-04-18 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
WO2011002910A1 (en) 2009-07-01 2011-01-06 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2011159760A1 (en) 2010-06-16 2011-12-22 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
EP2585444B1 (en) 2010-06-25 2014-10-22 Boehringer Ingelheim International GmbH Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
JP2013540801A (ja) 2010-11-02 2013-11-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 代謝異常の治療のための組合せ医薬
US20240025899A1 (en) * 2020-10-16 2024-01-25 Shanghai De Novo Pharmatech Co., Ltd. Triheterocyclic derivative, and pharmaceutical composition and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3686723T2 (de) * 1985-10-17 1993-04-01 Novonordisk As Oxadiazolylacetonitrile, ihre herstellung und anwendung.
DK155524C (da) * 1987-03-18 1989-09-11 Ferrosan As Kondenserede imidazolderivater og farmaceutiske praeparater indeholdende disse
DK443589D0 (da) * 1989-09-08 1989-09-08 Ferrosan As Heterocykliske forbindelser, deres fremstilling og anvendelse
DK151890D0 (da) * 1990-06-22 1990-06-22 Ferrosan As Heterocykliske forbindelser deres fremstilling og brug

Also Published As

Publication number Publication date
DK204291D0 (da) 1991-12-20
CA2125854A1 (en) 1993-07-08
AU3344893A (en) 1993-07-28
ZA929770B (en) 1994-06-17
NO942301D0 (no) 1994-06-17
IL104099A0 (en) 1993-05-13
WO1993013103A1 (en) 1993-07-08
JPH07502278A (ja) 1995-03-09
FI942963A0 (fi) 1994-06-20
EP0619820A1 (en) 1994-10-19
IL104099A (en) 1996-07-23
AU673814B2 (en) 1996-11-28
NO942301L (no) 1994-08-19
NZ246558A (en) 1995-07-26
FI942963L (fi) 1994-06-20
FI942963A7 (fi) 1994-06-20

Similar Documents

Publication Publication Date Title
TW211568B (cs)
JP4074509B2 (ja) 抗癌性化合物を製造するための方法と中間体
ES2367666T3 (es) Derivados de [4,5']bipirimidinil-6,4'-diamina como inhibidores de proteína quinasa.
JP6976947B2 (ja) 自己免疫疾患の処置に有用なビピラゾリル誘導体
TW209862B (cs)
CA2673003A1 (en) Quinazolines for pdk1 inhibition
CA2045359C (en) 1-indolyalkyl-4-(alkoxypyrimidinyl)piperazines
EA005407B1 (ru) Производные бензоимидазола, используемые в качестве антипролиферативного средства
CN103889987A (zh) 作为btk-抑制剂的4-咪唑并哒嗪-1-基-苯甲酰胺类和4-咪唑并三嗪-1-基-苯甲酰胺类
CA2727251A1 (en) 2 -arylaminoquinazolines for treating proliferative diseases
CN104341425B (zh) 氘代乙炔衍生物、其药物组合物及应用
EA017442B1 (ru) ПРОИЗВОДНЫЕ 2-АРИЛ-6-ФЕНИЛИМИДАЗО[1,2-a]ПИРИДИНОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ
BR112015019627B1 (pt) Compostos de amidas heterocíclicas, composições farmacêuticas compreendendo ditos compostos e usos dos mesmos para tratar colite ulcerativa, doença de crohn, artrite reumatoide, psoríase, espondiloartrite, artrite idiopática juvenil de aparecimento sistêmico (sojia), osteoartrite e esclerose múltipla
BR112015007731B1 (pt) Composto, composição farmacêutica que o compreende e uso do mesmo
JP2000309577A (ja) 抗がん剤として有用なヘテロ芳香族二環式誘導体
CN111410659B (zh) Pde9抑制剂及其用途
EA002907B1 (ru) Производные 6-фенилпиридил-2-амина, полезные в качестве ингибиторов nos
DE3883033T2 (de) Heterocyclische Verbindungen und ihre Herstellung und Anwendung.
US8957077B2 (en) Pyrazolopyrimidine PDE 10 inhibitors
PT781279E (pt) Quinoxalinodionas antagonistas do receptor de nmda
WO2021228248A1 (zh) 氮杂稠环酰胺类化合物及其用途
JP2017122103A (ja) うつ病、糖尿病及びパーキンソン病のような幾つかの障害の処置において使用するためのｔａａｒ調節薬としてのピラゾールカルボキサミド誘導体
UA57088C2 (uk) Похідні 4-оксо-3,5-дигідро-4н-піридазино-[4,5-b]індол-1-ацетаміду, лікувальний засіб та фармацевтична композиція
JP4220388B2 (ja) 異常な細胞増殖を処置するための置換された二環式誘導体の製造方法
TWI790810B (zh) Ret激酶抑制劑